With FDA Hold Lifted, Avidity Works To Bring First DM1 Therapy To Market

 
• By Joseph Haas
  
Dystrophin, skeletal muscle cell
Avidity can go ahead with its Phase III for a rare muscular disorder • Source: Shutterstock

More from Clinical Trials

More from R&D